Bosch John Roderick Ten Sells 1,417 Shares of Billiontoone (NASDAQ:BLLN) Stock

by · The Markets Daily

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) SVP Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62. Following the completion of the transaction, the senior vice president owned 27,884 shares of the company’s stock, valued at $2,589,308.24. The trade was a 4.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

  • On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total transaction of $169,920.00.
  • On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The shares were sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Stock Performance

BLLN traded down $0.49 on Wednesday, hitting $97.45. The company’s stock had a trading volume of 522,419 shares, compared to its average volume of 537,016. The company’s 50 day simple moving average is $116.72 and its 200-day simple moving average is $94.50. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44. The firm has a market cap of $4.48 billion and a P/E ratio of 139.21.

Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The firm had revenue of $109.45 million for the quarter. Analysts forecast that Billiontoone, Inc. will post 0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BLLN shares. JPMorgan Chase & Co. cut their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research cut their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Guggenheim started coverage on shares of Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective for the company. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $126.71.

View Our Latest Analysis on Billiontoone

Institutional Investors Weigh In On Billiontoone

Several large investors have recently added to or reduced their stakes in the business. Adams Street Partners LLC purchased a new stake in shares of Billiontoone in the 4th quarter valued at about $140,063,000. Baillie Gifford & Co. bought a new stake in shares of Billiontoone during the 4th quarter valued at about $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone during the fourth quarter worth about $39,717,000. JPMorgan Chase & Co. purchased a new position in shares of Billiontoone during the fourth quarter worth about $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone in the first quarter worth approximately $29,179,000.

About Billiontoone

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

Read More